Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Harm Reduction Therapeutics Introduces RiVive, Over-the-Counter Opioid Overdose Reversal Medication
Details : RiVive (naloxone HCl nasal spray) is an FDA approved, over-the-counter (OTC) medication which is indicated for the emergency treatment of opioid overdose.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Harm Reduction Therapeutics Introduces RiVive™, Over-the-Counter Opioid Overdose Reversal Medication
Details : RiVive (naloxone HCl) is a μ opioid receptor antagonist. It is an FDA-approved, over-the-counter medication approved for the emergency treatment of opioid overdose.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™, for the emergency treatment of known or suspected opioid overdose.
Product Name : Rivive
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 23, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Purdue Pharma
Deal Size : $29.9 million
Deal Type : Financing
Details : The proceeds will be used to fund commercial readiness for HRT’s low-cost over-the-counter (OTC) intranasal naloxone spray, tradename RiVive. Naloxone is an opioid antagonist rescue medication used to reverse the effects of a life-threatening opioid ov...
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 21, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Purdue Pharma
Deal Size : $29.9 million
Deal Type : Financing
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Harm Reduction Therapeutics’ Over-the-Counter Opioid Overdose Reversal Medication
Details : RiVive™ (Naloxone HCl Nasal Spray 3 mg) an opioid antagonist to be available over the counter (OTC) for the emergency treatment of life-threatening opioid overdose.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 08, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RiVive is an intranasal formulation of naloxone (3.0 mg) delivered as an atomized spray (0.1 ml) using a standard unit dose system for single administration.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 26, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revive (naloxone hydrochloride) is a safe and effective opioid antagonist, originally approved by the FDA in 1971 and has been used for decades by both medical professionals and the lay public to successfully reverse opioid overdoses.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under its terms, the contract manufacturer will produce Harm Reduction Therapeutics' nasal spray, RiVive™ (3.0mg naloxone), for the emergency treatment of known or suspected opioid overdose.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Purdue Pharma
Deal Size : $17.5 million
Deal Type : Financing
Details : The additional funding approved today will help HRT continue its work toward making OTC naloxone nasal spray available to the public. HRT plans to file a New Drug Application for naloxone nasal spray with FDA in 2022.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 23, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Purdue Pharma
Deal Size : $17.5 million
Deal Type : Financing
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Sage Chemical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HRT001 is an intranasal formulation of naloxone (3.0 mg) delivered as an atomized spray (0.1 ml) using a standard unit dose system for single administration. Its tentatively approved tradename is RiVive™.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Sage Chemical
Deal Size : Inapplicable
Deal Type : Inapplicable